West Pharmaceutical Services (NYSE:WST) Releases FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.850-9.050 for the period, compared to the consensus estimate of 8.610. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion. West Pharmaceutical Services also updated its Q3 2026 guidance to 2.140-2.240 EPS.

Wall Street Analyst Weigh In

WST has been the topic of a number of analyst reports. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. BNP Paribas Exane started coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price for the company. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Morgan Stanley boosted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, KeyCorp increased their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $363.17.

West Pharmaceutical Services Trading Down 0.1%

WST traded down $0.37 during trading hours on Thursday, reaching $358.04. 264,533 shares of the company’s stock traded hands, compared to its average volume of 893,653. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $335.41 and a 200 day moving average price of $286.58. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $386.00. The firm has a market capitalization of $25.30 billion, a PE ratio of 48.01, a PEG ratio of 2.91 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, sell-side analysts predict that West Pharmaceutical Services will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be given a dividend of $0.22 per share. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is currently 11.76%.

Insider Buying and Selling

In related news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by corporate insiders.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical posted Q2 2026 EPS of $2.37, ahead of the $2.08 consensus, while revenue of $872.3 million also topped estimates. The beat suggests strong operating momentum and is a key reason investors are bidding up the stock. West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
• Positive Sentiment: The company raised its 2026 outlook, guiding EPS to $8.85-$9.05 versus the prior/consensus view around $8.61, and revenue to about $3.3 billion-$3.4 billion. Higher guidance often supports the stock because it signals confidence in continued demand and earnings growth. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: Management also lifted Q3 2026 guidance, forecasting EPS of $2.14-$2.24 and revenue of $820 million-$835 million, both modestly above expectations. This reinforces the view that the earnings beat was not a one-quarter event.
• Positive Sentiment: Reuters noted demand remains strong for injectable-drug components tied to diabetes and obesity treatments, a favorable end-market trend that could continue to support West’s growth.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its position in West Pharmaceutical Services by 67.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after acquiring an additional 473,547 shares during the last quarter. Invesco Ltd. increased its position in shares of West Pharmaceutical Services by 3.1% during the fourth quarter. Invesco Ltd. now owns 908,625 shares of the medical instruments supplier’s stock worth $249,999,000 after purchasing an additional 27,340 shares in the last quarter. Corient Private Wealth LLC lifted its holdings in shares of West Pharmaceutical Services by 354.9% in the 4th quarter. Corient Private Wealth LLC now owns 128,841 shares of the medical instruments supplier’s stock valued at $35,449,000 after purchasing an additional 100,515 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of West Pharmaceutical Services by 6.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 8,629 shares of the medical instruments supplier’s stock valued at $2,374,000 after purchasing an additional 509 shares during the period. Finally, State of Tennessee Department of Treasury increased its position in West Pharmaceutical Services by 94.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 31,169 shares of the medical instruments supplier’s stock worth $8,576,000 after buying an additional 15,115 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.